Lung cancer screening and its implications
Professor Bob Steele CBE (Dundee, UK) discusses the potential implementation of a National Screening Programme in the UK, and the view post-NELSON, as well as highlighting the next steps in… read more.
Professor Bob Steele CBE (Dundee, UK) discusses the potential implementation of a National Screening Programme in the UK, and the view post-NELSON, as well as highlighting the next steps in… read more.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the… read more.
Tesaro has submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula (niraparib). The application was granted priority review and has an action date of 24 October 2019.
Dova Pharmaceuticals, Inc announced that the European Commission (EC) has granted marketing authorization for Doptelet (avatrombopag) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
Pacira BioSciences, Inc. announced that the company’s Marketing Authorization Application (MAA) for Exparel (bupivacaine liposome injectable suspension) for postsurgical analgesia was validated by the European Medicines Agency (EMA).
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
Dr Popat gives an update of the ongoing studies in mesothelioma in the UK
Dr Fiona McDonald (London, UK) discusses radical treatment for oligo metastatic NSCLC and if it should be the standard of care and Professor James Spicer (London, UK), the session Chair, gives… read more.
Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.
Article written by Maria Dalby. Interview by Hannah Chatfield. Among the clinical studies that reported results at the EHA congress 2019 was part 1 of the CASSIOPEIA study…. read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Another study with significant practice implications is the COLUMBA study, presented by Professor Maria-Victoria Mateos (University Hospital of Salamanca, Spain). This… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Oral selective BCL-2 inhibitor venetoclax has demonstrated encouraging clinical efficacy against MM. As monotherapy, venetoclax has shown to be… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.